A 24-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled extension study to assess the safety of CSJ117, when added to existing standard of care asthma therapy in patients ≥18 years of age who completed study CCSJ117A12201C - Trial PHRR211121-004083
Access comprehensive clinical trial information for PHRR211121-004083 through Pure Global AI's free database. This Phase 2 trial is sponsored by Novartis Healthcare Philippines, Inc. and is currently Terminated. The study focuses on Asthma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR211121-004083
Phase 2
Terminated
Trial Details
Philippine Health Research Registry • PHRR211121-004083
A 24-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled extension study to assess the safety of CSJ117, when added to existing standard of care asthma therapy in patients ≥18 years of age who completed study CCSJ117A12201C
Study Focus
Interventional
Sponsor & Location
Novartis Healthcare Philippines, Inc.
Argentina;Belgium;Bulgaria;Canada;Czech;Republic;Germany;Guatemala;Hungary;Italy;Japan;Latvia;Poland
Timeline & Enrollment
Phase 2
N/A
N/A
ICD-10 Classifications
Asthma
Asthma, unspecified
Nonallergic asthma
Mixed asthma
Predominantly allergic asthma
Data Source
Philippine Health Research Registry
PHRR211121-004083
Non-Device Trial